Accium BioSciences, Inc. And Radiant Research Forge Strategic Co-Marketing Agreement
10/19/2005 5:09:01 PM
SEATTLE--(BUSINESS WIRE)--June 16, 2005--Accium BioSciences, Inc. (Accium), the first US company to develop a fully commercial analytical facility dedicated to Accelerator Mass Spectrometry (AMS) services, has forged a new strategic co-marketing agreement with Radiant Research, Inc. (Radiant). This agreement combines Accium's expertise in AMS-based study design and in-house analytical services with Radiant's state-of-the-art clinical trials facilities to provide pharmaceutical researchers with comprehensive Phase 0 (microdosing) and low radiation Phase I clinical services nationwide.
"For the first time, this partnership provides our pharmaceutical sponsors with a one-stop solution for both the clinical and analytical components of early phase clinical trials," stated Ali Arjomand, Ph.D., President and Chief Operating Officer of Accium BioSciences. "Radiant is leading the way in early phase clinical trial services in the US and Accium is pleased to be working with Radiant's experienced investigators, research professionals and business development teams."
comments powered by